4P-Pharma, a clinical-stage biotechnology company and the research center Institut de la Vision (Sorbonne Université, Inserm, CNRS) establish a partnership agreement for the development of 4P020, a promising therapeutic approach for dry age-related macular degeneration (dAMD) and Stargardt disease with the support of the SATT Lutech.
This drug candidate, initially studied by Dr Valerie Fontaine at the Institut de la Vision, opens a new therapeutic strategy for these diseases.
“This public-private partnership demonstrates our shared commitment to develop breakthrough and novel therapies that can have a meaningful impact for the millions of patients suffering from dAMD and Stargardt disease worldwide,” says Revital Rattenbach, chairwoman of 4P-Pharma. “Our goal is to accelerate the development of this innovative drug and bring it to the clinic as quickly as possible”.
Valerie Fontaine’s team at IDV From left to right Elodie MONTEIRO, Thinhinane BOUMEDINE, Valérie FONTAINE, Cécile VIDAL
Urodelia, a Toulouse (France) biotech company specialized in personalised anti-cancer therapeutic vaccine, and 4P-Pharma, a Lille (France) biotech company specialised in human and animal drug development, are pleased to announce that they established a business development partnership. As an exclusive partner, 4P-Pharma will seek strategic opportunities in Animal Health for the licensing-out of Urodelia’s Apa.vac® anticancer therapeutic vaccine.